{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:43:09Z","timestamp":1790383389916,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.autrev.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T17:36:28Z","timestamp":1551720988000},"page":"510-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Refractory lupus nephritis: When, why and how to treat"],"prefix":"10.1016","volume":"18","author":[{"given":"Andreas","family":"Kronbichler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Brezina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Gauckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2019.03.004_bb0005","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0020","first-page":"332","article-title":"Renal biopsy in lupus patients with low levels of proteinuria","volume":"34","author":"Christopher-Stine","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0025","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Duran-Barragan","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0961203309351541","article-title":"Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients","volume":"19","author":"Garcia-Carrasco","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0040","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar1954","article-title":"Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study","volume":"8","author":"Vigna-Perez","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.03.004_bb0045","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1177\/0961203311409273","article-title":"Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus","volume":"20","author":"Pinto","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0050","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/0961203309358599","article-title":"Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience","volume":"19","author":"Lateef","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0055","first-page":"565039","article-title":"Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus","volume":"2012","author":"Bang","year":"2012","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0060","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0065","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1093\/ndt\/gfq256","article-title":"Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus","volume":"25","author":"Catapano","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.03.004_bb0070","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0075","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2215\/CJN.04030808","article-title":"Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome","volume":"4","author":"Melander","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0085","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study","volume":"21","author":"Fernandez-Nebro","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0090","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0961203317749047","article-title":"Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus","volume":"27","author":"Iwata","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0095","series-title":"Clinical Practice Guideline for Glomerulonephritis","author":"KDIGO","year":"2012"},{"key":"10.1016\/j.autrev.2019.03.004_bb0100","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfv102","article-title":"Lupus nephritis management guidelines compared","volume":"31","author":"Wilhelmus","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.03.004_bb0105","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the euro-lupus nephritis trial","volume":"50","author":"Houssiau","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0110","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ki.2010.525","article-title":"Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus","volume":"79","author":"Reich","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2019.03.004_bb0115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0120","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfr517","article-title":"Strategy for second kidney biopsy in patients with lupus nephritis","volume":"27","author":"Alsuwaida","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.03.004_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000018","article-title":"Role of early repeated renal biopsies in lupus nephritis","volume":"1","author":"Zickert","year":"2014","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0130","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/rheumatology\/41.8.876","article-title":"Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents","volume":"41","author":"Karim","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0135","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"Diaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.004_bb0140","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.11467","article-title":"Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus","volume":"49","author":"Ward","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0145","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0002-9343(91)90151-M","article-title":"Morbidity of systemic lupus erythematosus: role of race and socioeconomic status","volume":"91","author":"Petri","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archdermatol.2011.2558","article-title":"Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study","volume":"148","author":"Frances","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0155","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/ckj\/sfu096","article-title":"Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease","volume":"7","author":"Jones","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.autrev.2019.03.004_bb0160","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0165","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000365256","article-title":"Mycophenolate in refractory and relapsing lupus nephritis","volume":"40","author":"Rivera","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0175","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0180","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0185","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12013-014-0437-z","article-title":"Effect of rituximab on serum levels of anti-C1q and Antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis","volume":"72","author":"Zhang","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.autrev.2019.03.004_bb0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1741-7015-11-95","article-title":"Renal involvement in autoimmune connective tissue diseases","volume":"11","author":"Kronbichler","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0195","first-page":"449","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre Registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0200","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10067-015-3166-9","article-title":"Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review","volume":"35","author":"Contis","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0205","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0210","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/0961203316641768","article-title":"Risk of clinical deterioration in patients with lupus nephritis receiving rituximab","volume":"25","author":"Manou-Stathopoulou","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0215","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","article-title":"APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth","volume":"188","author":"Hahne","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0220","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.autrev.2017.11.013","article-title":"Belimumab in the treatment of systemic lupus erythematous: an evidence based review of its place in therapy","volume":"17","author":"Marcondes","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.004_bb0235","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0240","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keu369","article-title":"Belimumab after rituximab as maintenance therapy in lupus nephritis","volume":"53","author":"Kraaij","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0245","first-page":"643","article-title":"Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series","volume":"36","author":"Gualtierotti","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2019.03.004_bb0255","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","article-title":"B cell therapy in ANCA-associated vasculitis: current and emerging treatment options","volume":"14","author":"McClure","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0260","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.autrev.2017.04.007","article-title":"Rituximab for immunologic renal disease: what the nephrologist needs to know","volume":"16","author":"Kronbichler","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.004_bb0265","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.03.004_bb0270","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/rheumatology\/keu475","article-title":"Ofatumumab: a novel treatment for severe systemic lupus erythematosus","volume":"54","author":"Thornton","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0285","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multitarget therapy","volume":"19","author":"Bao","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0290","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1093\/ndt\/gfq322","article-title":"Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases","volume":"25","author":"Cortes-Hernandez","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.03.004_bb0295","first-page":"62","article-title":"Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study","volume":"31","author":"Fei","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0300","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/0961203310366573","article-title":"Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis","volume":"19","author":"Lee","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0305","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0961203310365714","article-title":"Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis","volume":"19","author":"Lanata","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0310","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0961203309350320","article-title":"Efficacy and safety of cyclosporine a in patients with refractory systemic lupus erythematosus in a daily clinical practice","volume":"19","author":"Ogawa","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0315","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1177\/0961203318758508","article-title":"Multitarget therapy of mycophenolate mofetil and cyclosporine a for induction treatment of refractory lupus nephritis","volume":"27","author":"Jesus","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0320","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2019.03.004_bb0325","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis. The lupus nephritis collaborative study group","volume":"326","author":"Lewis","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0330","first-page":"296","article-title":"Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the lupus Plasmapheresis study group","volume":"145","author":"Euler","year":"1994","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0335","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(199803)41:3<414::AID-ART6>3.0.CO;2-N","article-title":"Severe infections in plasmapheresis-treated systemic lupus erythematosus","volume":"41","author":"Aringer","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0340","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/art.1780371212","article-title":"Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide","volume":"37","author":"Euler","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0345","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000367682","article-title":"Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two","volume":"38","author":"Zollner","year":"2014","journal-title":"Blood Purif"},{"key":"10.1016\/j.autrev.2019.03.004_bb0350","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2004.029660","article-title":"IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study","volume":"64","author":"Stummvoll","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0355","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/ndt\/gfr239","article-title":"Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity","volume":"27","author":"Stummvoll","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2019.03.004_bb0360","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2015.08.010","article-title":"Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review","volume":"15","author":"Kronbichler","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.004_bb0365","first-page":"1029","article-title":"Plasmapheresis for lupus nephritis","volume":"327","author":"Wallace","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2019.03.004_bb0370","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1191\/0961203304lu525oa","article-title":"Autologous stem cell transplantation for systemic lupus erythematosus","volume":"13","author":"Jayne","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0375","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/0961203312470729","article-title":"Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry","volume":"22","author":"Alchi","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0380","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.295.5.527","article-title":"Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus","volume":"295","author":"Burt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2019.03.004_bb0385","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41409-018-0173-x","article-title":"Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome","volume":"53","author":"Burt","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.autrev.2019.03.004_bb0390","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/annrheumdis-2018-214024","article-title":"Tolerising cellular therapies: what is their promise for autoimmune disease?","volume":"78","author":"Mosanya","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0395","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0400","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10067-014-2754-4","article-title":"Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy","volume":"33","author":"Gu","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0405","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.stemcr.2018.01.029","article-title":"A long-term follow-up study of allogeneic Mesenchymal stem\/stromal cell transplantation in patients with drug-resistant systemic lupus Erythematosus","volume":"10","author":"Wang","year":"2018","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.autrev.2019.03.004_bb0410","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/art.27548","article-title":"Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus","volume":"62","author":"Sun","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0415","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.03.004_bb0420","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0425","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2017.03.008","article-title":"Autologous hematopoietic stem cell transplantation in systemic lupus Erythematosus and antiphospholipid syndrome: a systematic review","volume":"16","author":"Leone","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.004_bb0430","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/ard.2005.044248","article-title":"Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial","volume":"65","author":"Tam","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0435","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/art.10752","article-title":"High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus","volume":"48","author":"Petri","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0440","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/s10165-012-0645-6","article-title":"Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis","volume":"23","author":"Nishi","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0445","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0049-0172(00)80018-9","article-title":"Intravenous immunoglobulin treatment of lupus nephritis","volume":"29","author":"Levy","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.03.004_bb0450","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10067-004-1002-8","article-title":"High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide","volume":"24","author":"Benenson","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0455","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/ard.2003.008342","article-title":"Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis","volume":"63","author":"Lehman","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0460","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10067-016-3511-7","article-title":"Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis","volume":"36","author":"Raturi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0465","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0470","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0475","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/eji.201847492","article-title":"Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors","volume":"48","author":"Alexander","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2019.03.004_bb0480","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1177\/0961203317691371","article-title":"Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases","volume":"26","author":"Sjowall","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2019.03.004_bb0485","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0490","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/annrheumdis-2013-204986","article-title":"Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial","volume":"74","author":"Hambardzumyan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.004_bb0495","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.autrev.2018.07.007","article-title":"Target therapy in SLE","volume":"18","author":"Schneider","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.004_bb0500","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2019.03.004_bb0505","doi-asserted-by":"crossref","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","article-title":"Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients","volume":"68","author":"Silva","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.autrev.2019.03.004_bb0510","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:14:14Z","timestamp":1761599654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219300576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1568997219300576"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.03.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory lupus nephritis: When, why and how to treat","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}